Lisette Hilton


Venetoclax monotherapy for cutaneous BPDCN

November 11, 2020

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

Skin of color patients lacking in psoriasis trials

November 03, 2020

A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.

730 nm picosecond laser safe, effective for benign pigmented lesions

October 13, 2020

Lasers typically used for tattoo removal are on the rise as a possible treatment for melasma, with the novel 730 nm picosecond laser (PicoWay, Candela) being the most recently studied device which showed to be safe and effective for treating benign pigmented lesions.

CD123-targeted therapies promising in BPDCN and AML

October 06, 2020

Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.

The science behind skin care for sensitive skin

September 22, 2020

The problem of sensitive skin has risen dramatically in the last decade, highlighting the need for affordable, effective and scientifically-formulated and tested products designed especially for people with sensitive skin.

Skin of color patients lacking in phase 3 psoriasis trials

September 17, 2020

An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.

Tagraxofusp comparable to other chemo regimens as first-line therapy

September 04, 2020

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.